Medicus Pharma Ltd.
June 17, 2025
Company Presentation
Oncology
153A
Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Our lead asset, SkinJect Inc., is a development stage biotechnology life sciences company focused on commercializing novel treatment for non-melanoma skin cancer, especially basal cell carcinoma (BCC), using a patented dissolvable doxorubicin-containing microneedle array (D-MNA). D-MNA delivers the chemotherapeutic agent trans dermally at the site of the lesion to eradicate tumor cells.
D-MNA is in a placebo controlled, double blinded Phase 2 trial. Patient recruitment is currently underway in nine (9) sites in United States.
We are actively seeking to collaborate with strategic partners to complete the clinical development program and bring D-MNA to market. The company is also exploring to opportunistically expand its drug development pipeline through acquisitions and partnerships.
Company HQ City:
Conshohoken
Company HQ State:
PA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
Skinject
CEO
RAZA BOKHARI, MD
Development Phase of Lead Product
Phase II
Exchange
NASDAQ
Ticker
MDCX
When you expect your next catalyst update?
Closing of Antev Limited UK acquisition announced on April 28th 2025. Antev is a clinical stage biotech company, developing Teverelix, a next generation GnRH antagonist, as first in market product for cardiovascular high-risk prostate cancer patients and patients with first acute urinary retention (AURr) episodes due to enlarged prostate.
What is your next catalyst (value inflection) update?
June 2025
Website
https://medicuspharma.com
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}